Dyadic International (DYAI) Operating Income (QoQ) (2018 - 2026)
Powered by 
Analysis
Dyadic International (DYAI) Operating Income (QoQ) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.78 Bn | 192.79 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.92 Bn | 176.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 131.39 Bn | 123.54 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.91 Bn | 73.91 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.35 Bn | 55.17 Bn | 1.37 Bn |
| 6 | Moderna | 53.67 Bn | 48.54 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.12 Bn | 29.81 Bn | 992.69 Mn |
| 8 | Biogen | 31.92 Bn | 30.63 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.23 Bn | 29.23 Bn | 1.16 Mn |
| 10 | Dyadic International | 17.65 Mn | 9.69 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -23.88% |
| Dec 31, 2025 | 20.23% |
| Sep 30, 2025 | -11.35% |
| Jun 30, 2025 | 13.65% |
| Mar 31, 2025 | -30.88% |
| Dec 31, 2024 | -655.16% |
| Sep 30, 2024 | 90.08% |
| Jun 30, 2024 | 3.90% |
| Mar 31, 2024 | 1.99% |
| Dec 31, 2023 | -26.08% |
| Sep 30, 2023 | 24.90% |
| Jun 30, 2023 | -11.70% |
| Mar 31, 2023 | 8.44% |
| Dec 31, 2022 | -20.18% |
| Sep 30, 2022 | 43.84% |
| Jun 30, 2022 | -20.89% |
| Mar 31, 2022 | 34.90% |
| Dec 31, 2021 | -26.83% |
| Sep 30, 2021 | 14.04% |
| Jun 30, 2021 | 99.88% |